Deep-value stocks like Supernus Pharmaceuticals and Party City look attractive now.
News & Analysis: Supernus Pharmaceuticals
SUPN earnings call for the period ending March 24, 2019.
Exelixis and Supernus Pharmaceuticals are deeply undervalued healthcare plays.
SUPN earnings call for the period ending December 31, 2018.
Think software-as-a-service, neurology drugs, and marijuana.
Find out why our healthcare contributors believe that these biotechs are great buys right now.
Sometimes good news just isn't good enough.
If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.
These three relatively small biotechs could be just the ticket.
Shares sell off after the company posts mixed second-quarter results. Here's what investors need to know.